Cautionary Statements Regarding Forward-Looking Information

Size: px
Start display at page:

Download "Cautionary Statements Regarding Forward-Looking Information"

Transcription

1 Investor Handout November 2016

2 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual results to differ materially include the following: the risk that Monsanto Company s ( Monsanto ) stockholders do not approve the transaction; uncertainties as to the timing of the transaction; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected time-frames or at all and to successfully integrate Monsanto s operations into those of Bayer Aktiengesellschaft ( Bayer ); such integration may be more difficult, timeconsuming or costly than expected; revenues following the transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the transaction; the retention of certain key employees at Monsanto; risks associated with the disruption of management s attention from ongoing business operations due to the transaction; the conditions to the completion of the transaction may not be satisfied, or the regulatory approvals required for the transaction may not be obtained on the terms expected or on the anticipated schedule; the parties ability to meet expectations regarding the timing, completion and accounting and tax treatments of the merger; the impact of indebtedness incurred by Bayer in connection with the transaction and the potential impact on the rating of indebtedness of Bayer; the effects of the business combination of Bayer and Monsanto, including the combined company s future financial condition, operating results, strategy and plans; other factors detailed in Monsanto s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the SEC ) for the fiscal year ended August 31, 2016 and Monsanto s other filings with the SEC, which are available at and on Monsanto s website at and other factors discussed in Bayer s public reports which are available on the Bayer website at Bayer assumes no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Disclaimer

3 Additional Information and Where to Find It This communication relates to the proposed merger transaction involving Monsanto Company ( Monsanto ) and Bayer Aktiengesellschaft ( Bayer ). In connection with the proposed merger, Monsanto and Bayer intend to file relevant materials with the U.S. Securities and Exchange Commission (the SEC ). Monsanto has filed with the SEC a preliminary proxy statement on Schedule 14A and will file and provide to Monsanto stockholders a definitive proxy statement (the Proxy Statement ) that will contain important information regarding the proposed merger. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, and is not a substitute for the Proxy Statement or any other document that Monsanto may file with the SEC or send to its stockholders in connection with the proposed merger. STOCKHOLDERS OF MONSANTO ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE DEFINITIVE PROXY STATEMENT, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC s website, and Monsanto s website, and Monsanto stockholders will receive information at an appropriate time on how to obtain transaction-related documents for free from Monsanto. In addition, the documents (when available) may be obtained free of charge by directing a request to Corporate Secretary, Monsanto Company, 800 North Lindbergh Boulevard, St. Louis, Missouri 63167, or by calling (314) Participants in Solicitation Monsanto, Bayer and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Monsanto common stock in respect of the proposed transaction. Information about the directors and executive officers of Monsanto is set forth in the proxy statement for Monsanto s 2016 annual meeting of stockholders, which was filed with the SEC on December 10, 2015, and in Monsanto s Annual Report on Form 10-K for the fiscal year ended August 31, 2016, which was filed with the SEC on October 19, Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. Disclaimer

4 Building Leading Life Science Businesses to Create Value Division Leadership Position Pharmaceuticals Leading position in cardiology, hematology, radiology, women s health Consumer Health Global #1 OTC business with strong portfolio of leading brands Crop Science / Animal Health After the acquisition of Monsanto, a global leader in seeds, traits, crop protection and digital farming; #5 globally in Animal Health Page 1 Investor Handout November 2016 Monsanto Acquisition - Transformative Step to Strengthen Life Science Portfolio 2015 Pro Forma Life Science Sales Crop Science Industry Leadership Creating a global leader in agriculture with an integrated agricultural offering Broad product portfolio and R&D pipeline to deliver enhanced solutions for farmers Total 47.1bn 49% combined pro forma Significant Value Creation Substantial synergy potential Accretion to core EPS in the first full year Potential for premium valuation of combined agriculture business Health care businesses 49% Excluding Covestro Monsanto sales calculated at avg Fx rate (USD/EUR=1.11) Monsanto Consistent with Bayer s Strategy Agriculture market driven by innovation Attractive long-term growth market Building of leadership position Page 2 Investor Handout November 2016

5 Key Metrics of the Monsanto Transaction Offer Summary All-cash consideration of $128 per Monsanto share Enterprise value (EV) of $66bn including net debt Transaction unanimously approved by Monsanto s Board of Directors, Bayer s Board of Management and Bayer s Supervisory Board Key Metrics Premium of 44% to Monsanto s undisturbed share price of $89.03 (1) Premium of 43% to Monsanto s three-month volume weighted average share price (1) LTM (2) EBITDA multiple of 18.6x as of May 31, 2016; consensus (3) FY 2017 EBITDA multiple of 16.5x (1) As of May 9, 2016, the day before Bayer s first written proposal to Monsanto; (2) Last Twelve Months (3) as per Bloomberg, Sep 13, 2016; Fx rate: USD/EUR=1.11 Page 3 Investor Handout November 2016 Key Metrics of the Monsanto Transaction (cont d) Value Creation Financing Significant value creation through expected synergies confirmed in due diligence: ~$1.5bn annual net synergies after year three (~80% cost, ~20% sales) Additional synergies from integrated solutions increasing over the years thereafter Transaction expected to be accretive to core EPS in the first full year after closing; double-digit percentage core EPS accretion expected in the third full year after closing Expect to earn cost of capital after year 4 post closing Permanent financing expected to consist of a combination of debt and equity Expected equity component of ~$19bn, expected to be raised through issuance of mandatory convertible bonds and through a rights issue with subscription rights Page 4 Investor Handout November 2016

6 Path to Completion of the Monsanto Transaction September 14, 2016: Signing of merger agreement between Bayer and Monsanto September, 2016: Commenced discussions with regulatory agencies October 12, 2016: Closing of syndication of $57bn bank facilities; refinancing might be executed in part well in advance of expected closing Q4 2016: Submission of regulatory filings in the US December 13, 2016: Monsanto to convene shareholder meeting to vote on merger agreement Q1 2017: Intended antitrust regulatory filing in the European Union Closing expected by the end of 2017 Page 5 Investor Handout November 2016 Proven Track Record of Successful Portfolio Management Rebuilding Pharma Total transaction value Number of closed transactions Strengthening HealthCare and CropScience Transforming into a Life Science company Roche OTC Schering Stoneville Cotton Seed Athenix Conceptus Steigerwald AgraQuest Dihon Algeta Merck OTC Signing of merger agreement with Monsanto Lanxess Diagnostics H.C. Starck Wolff Walsrode Interventional Covestro (partial IPO) Transforming into a Life Science company total transaction value of ~ 52bn in ~130 closed deals since 2005 Diabetes Care Page 6 Investor Handout November 2016

7 Clear Portfolio Management Criteria Drive Value Generation General Portfolio Criteria Focus on markets with long-term GDP+ growth potential Ability to generate attractive returns Success driven by innovation-based business models Potential to achieve leadership positions Bayer as the best owner Portfolio Management Approach Decisions based on regular portfolio review and market opportunity Strong DCF-based value creation imperative Key performance indicators including sales growth relative to market, core EPS accretion and value generation No capital allocation to one business at the cost of underinvestment in another business Proven integration/ separation capabilities Page 7 Investor Handout November 2016 Delivering Shareholder Value Through Strong Execution 3.2 Building Leading Life Science Franchise Sales and EBITDA Margin 1 Rebuilt Pharma Global Leadership in Consumer Health ~ Sales, bn EBITDA Margin, % figures restated, Crop Science as reported; pro forma combined EBITDA margin; Monsanto calendarized to December 2015 year-end; 3 From December 31, 2004 through September 13, Building a New Leader in Crop Science Monsanto Increased market cap ~4x since Proven Integration Track Record Experienced acquirer having successfully integrated various multi-billion transactions Aventis CropScience Schering Roche OTC Merck & Co. Consumer Care Monsanto integration expected to be no more complex than previous large integrations Page 8 Investor Handout November 2016

8 Consistent Track Record of Strong Operating Performance CAGR Sales +6% Adj. EBITDA +8% Core EPS +10% Sales ( bn) Adj. EBITDA ( bn) Adj. EBITDA margin (%) Core EPS ( ) Continued businesses for 2014/2015; 2015 figures restated Adj. EBITDA: EBITDA before special items Page 9 Investor Handout November 2016 September YTD 2016 Successful Operating Performance and Strategic Progress Sales m, % FX & portf. adj. 34,800 34,949 9M 15 9M 16 +3% EBITDA before special items, m 8,340 9,123 9M 15 9M 16 +9% EBIT m 5,320 6,253 9M 15 9M % Core EPS cont. operations, M 15 9M 16 +7% Highlights 9M 2016 New approvals for Kovaltry and Xofigo Patent term for Rivaroxaban extended in USA Stake in Covestro reduced to 64% Acquisition of Monsanto agreed Sale of the Consumer Business of Environmental Science completed Outlook for core EPS 2016 raised Peak sales estimate for recently launched pharma products raised to > 10 billion Mid-term aspirations emphasize attractive growth and margin potential 2015 figures restated Page 10 Investor Handout November 2016

9 FY 2016 Group Outlook Raised Sales % yoy Fx and portfolio adj., EBITDA before special items; Continuing operations update October Sales Adj. EBITDA Group 46.1bn Low-single-digit % increase to 46 47bn Life Sciences 34.1bn Mid-single-digit % increase to ~ 35bn Group 10.3bn High-single-digit % increase Life Sciences 8.6bn Mid- to high-single-digit % increase Core EPS 6.82 High-single-digit % increase 2015 figures restated Assuming end Q Fx rates (USD 1.12) Outlook depends on specific planning assumptions as detailed in the Annual Report Page 11 Investor Handout November 2016 Mid-Term Aspirations Emphasize Attractive Growth and Margin Potential Sales Growth CAGR Pharma ~6% Consumer Health Adjusted EBITDA Margin % Despite dilution through Radiology and significant R&D investment 4-5% ~25% Animal Health 4-5% 23-24% Crop Science (incl. Monsanto)* Above market growth >30% after year 3 post closing Sales Fx & portf. adjusted, EBITDA before special items, continuing operations Outlook depends on specific planning assumptions outlined in the Interim Report Q * Not including any potential divestments Page 12 Investor Handout November 2016

10 Increased Underlying Pharma Margin Expectations for 2018 Pharma EBITDA margin before special items 32 34% Depending on level of R&D investment 32 34% Depending on level of R&D investment -0.8% pts +1.1% pts -0.6% pts +0.3% pts Aspiration 2017 Margin Dilution by RAD 1 Higher R&D Investment 2 Fx Performance Aspiration 2018 As of March 2015 As of September ) RAD: Radiology business became part of Pharma effective Jan. 1, ) Current planning for 2018 compared to planning in 2015 Page 13 Investor Handout November 2016 Focused Leadership Strategy at Pharma to Deliver Growth and to Create Value Deliver Growth Drive Innovation Create Value Focus on key therapeutic areas and build / maintain leading positions Cardiovascular Hemophilia Women s Health Oncology Continue to maximize growth potential of Xarelto, Eylea, Xofigo, Stivarga, Adempas Build pipeline organically and pursue in-licensing and bolt-on M&A options Focus research on Cardiovascular and Oncology Foster late-stage development to fully develop high value projects Support leading positions in Hemophilia, Women s Health and Ophthalmology Deliver on mid-term growth and margin aspirations Balance margin expansion and need to invest in securing longterm growth Page 14 Investor Handout November 2016

11 Combined Peak Sales Potential of Recently Launched Products Increased to > 10bn > 5bn > 2.5bn ~ 3.5bn 1.5bn 1bn > 1bn Old PSP Xarelto New PSP* Old PSP Eylea New PSP* Old PSP Xofigo New PSP* > 10bn 1bn 1bn 7.5bn 0.5bn > 0.5bn Old PSP Stivarga New PSP* Old PSP Adempas New PSP* Old PSP New PSP* Rec. Launched Products * PSP: peak sales potential Page 15 Investor Handout November 2016 Consumer Health to Maintain Global OTC Leadership and to Improve Profitability Build Global Brands Drive Key Market Growth Accelerate Innovation Focus on categoryleading, global brands Execute brand strategies in a differentiated, country-specific approach, tailored to local market requirements Deliver growth in key markets including USA, China, Brazil, Russia Refocus investments to mature markets which are regaining momentum Continue prudent investments in emerging markets Leverage scale to grow more profitably Accelerate consumercentric innovation Create more effective innovation processes Exploit growth potential of Rx/OTC switches Build new digital capabilities Page 16 Investor Handout November 2016

12 Broad Portfolio of Consumer Health Brands with Sales of > 100 million p.a. Each Sales FY million* 627 million 413 million 355 million 267 million 253 million 251 million** 218 million 211 million 162 million 159 million 158 million * including Rx Aspirin Cardio ** Alka Seltzer family 128 million 111 million 110 million Page 17 Investor Handout November 2016 Key Takeaways Two Years After the Acquisition of Merck & Co s Consumer Care Business Key brands (e.g. Coppertone & Dr. Scholl s) were underinvested Weak product pipeline (low visibility during bidding process) Product discontinuation (Oxytrol) Underestimated country risk from Emerging Markets volatility Stronger business disruption than anticipated during integration of Merck Consumer Care & Dihon in China Focus on delivering the full potential of Merck & Co. Consumer Care by Increased investment in key brands Rebuilding Coppertone and Dr. Scholl s Driving growth in the USA supported by significant new product introductions Page 18 Investor Handout November 2016

13 Combined Crop Science Company Well Positioned to Deliver Superior Performance Integrated Solutions Lead Innovation Deliver Value Proposition Create integrated agriculture offerings Fully leverage combinations and optimized usage of products based on agronomic advice and digital farming Enable integrated solutions for broad-acre crops corn and soy Advance strong pipeline across crops, indications and technologies Deploy joint innovation capabilities to deliver enhanced solutions for the next generation of farming Deliver integrated systems based on technologies optimally designed to work together Realize full synergy potential of the combined businesses Deliver above market growth and superior margins Page 19 Investor Handout November 2016 Significant Strategic Benefits Due to Strong Position Along Key Criteria Scale A leading player with significant revenue base and high R&D spend Breadth Broad product portfolio across indications and crops R&D Pipeline Integrated Solutions Digital Farming Best-in-class combination of science, innovation history and R&D effort globally Combination of the high-quality seeds & traits and crop protection pipelines across key crops Ability to provide farmers with integrated solutions immediately and into the future Opportunity to create a global leader by combining strengths of both organizations in digital farming Page 20 Investor Handout November 2016

14 Confidence in Our R&D Investments R&D 2016e: ~ 4.5bn Pharma 58% 25% 3% 6% Crop Science Animal Health Covestro 6% Recon. 2% Consumer Health Achievements 55 projects in clinical development at Pharma 30 successful phase III clinical trials at Pharma since 2010 Strengthened brands through multiple line or product introductions at Consumer Health Launched 12 active ingredients between 2006 and 2016 at Crop Science New product introductions at Animal Health (Seresto, Zelnate / Victrio) Page 21 Investor Handout November 2016 Increased R&D Spending at Pharma - Significant Investment in Life Cycle Management 2015 R&D Investment at Pharma Research ~20% 2,402m Life Cycle Management ~45% billion; R&D as % of sales ~35% Development Pharma including Radiology Page 22 Investor Handout November 2016

15 Key Pharma Pipeline Assets With Combined Peak Sales Potential of 6 billion Pipeline Project Indication Peak Sales Potential Vericiguat 1 Worsening chronic heart failure ~ 0.5bn Finerenone Diabetic kidney disease 1.0bn Vilaprisan Uterine fibroids 1.0bn BAY (ODM-201) Non-metastatic castration-resistant prostate cancer Metastatic hormone-sensitive prostate cancer 1.0bn Anetumab Various cancers 2 2.0bn Copanlisib Lymphoma 0.5bn 1) In cooperation with Merck & Co. 2) Ovarian, Mesothelioma, etc. Page 23 Investor Handout November 2016 New Product and Life Cycle Management Launches Planned at Pharma Xarelto LCM MACE ESUS CHF Med. ill Copanlisib Lymphoma Xofigo combo Damoctocog alpha Anetumab Cancer Xarelto LCM ACS dual Amikacin inhale ODM-201 nmcrpc Xarelto LCM PAD Vericiguat WCHF Riociguat Syst. Sclerosis Anetumab Cancer Stivarga HCC 2L Visanne Endo Tedizolide Finerenone DKD Vilaprisan UF Xofigo Breast ODM-201 mhspc First expected launches in first countries; Eylea Life Cycle Management not included Selection of projects, regional and small projects not shown; Launches subject to successful clinical development and regulatory approval Page 24 Investor Handout November 2016

16 Robust Consumer-Centric Innovation at Consumer Health ClariSpray 24-hour nasal glucocorticoid formulated to relieve nasal allergy symptoms Aleve PM Analgesic for relief of occasional sleeplessness when associated with minor aches and pains Micro Active Aspirin New formulation of Aspirin that works twice as fast as previous Aspirin tablets Bepanthen Sun Specialist suncare leveraging Bepanthen s strong dermatology equity and Bayer s health credentials Berocca On-the-Go Food supplement rich in vitamins and minerals formulated as orodispersable tablet Examples only Page 25 Investor Handout November 2016 Creation of a Leading Innovator 2015 Pro Forma R&D Investment ( bn) 1 Combined Strength in Innovation 2 Crop Protection 2.5 Seeds & Traits Total > 40 major R&D sites worldwide 1.6 > 200 breeding stations in all relevant geographies ~10,000 employees in R&D Strong R&D technology platform % of Sales Bayer CS + Monsanto Dow Ag + DuPont Ag Syngenta + ChemChina Ag BASF Ag 11.4 Cross-technology capabilities > 70 pipeline advancements over last two years Strong pipeline across crops, indications and technologies 1 Based on company information and internal calculations excl. synergies (at avg Fx rate USD/EUR=1.11) 2 Pro forma; 3 BASF: includes ~ 150 million for Plant Science Page 26 Investor Handout November 2016

17 Bayer A World-Class Life Science Company Value- Creating Portfolio Management Creating a global leader in agriculture through acquisition of Monsanto Proven integration/separation capabilities Track record of delivering shareholder value through successful portfolio management Continuous Prosperous Performance Excellence in Innovation to Foster Future Growth Mid-term aspirations emphasize growth and margin potential Pharma launch products expected to drive growth; PSP increased to > 10bn Consumer health challenges addressed Crop Science expected to benefit from cyclical market upswing and long-term GDP+ growth potential Upcoming new product launches and LCM at Pharma expected to mitigate LoE post 2023 Combined PSP of key late-stage Pharma pipeline assets 6bn Consumer Health delivering steady stream of consumer-centric innovations Strong R&D capabilities at combined Crop Science business LCM: Life Cycle Management; LoE: Loss of exclusivity; PSP: Peak sales potential Page 27 Investor Handout November 2016

18 Date Event Publication Wednesday, February 22, 2017 Thursday, April 27, 2017 Friday, April 28, 2017 Thursday, July 27, 2017 Thursday, October 26, 2017 Investor Conference Call Investor Conference Call Annual Stockholders Meeting Investor Conference Call Investor Conference Call 2016 Annual Report Q Interim Report Q Interim Report Q Interim Report Reporting Events

19 Dr. Jürgen Beunink Phone: Peter Dahlhoff Phone: Judith Nestmann Phone: Constance Spitzer Phone: Prof. Dr. Olaf Weber Phone: Contacts

Cautionary Statements Regarding Forward-Looking Information

Cautionary Statements Regarding Forward-Looking Information Investor Handout December 2016 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could

More information

News Release. Bayer shows strong performance Acquisition of Monsanto agreed. Third quarter of 2016:

News Release. Bayer shows strong performance Acquisition of Monsanto agreed. Third quarter of 2016: News Release Bayer AG Corporate Brand, Communications & Government Relations 51368 Leverkusen Germany Phone +49 214 30-0 www.news.bayer.com Third quarter of 2016: Bayer shows strong performance Acquisition

More information

Investor Conference Call

Investor Conference Call Investor Conference Call /////////// Q2 2018 Results September 05, 2018 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information Certain statements contained

More information

Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition

Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com First quarter of 2018 Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition

More information

Bayer: Good performance in a challenging environment, Group outlook confirmed

Bayer: Good performance in a challenging environment, Group outlook confirmed Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Third quarter of 2018 Bayer: Good performance in a challenging environment, Group outlook confirmed Group sales

More information

Q Analyst and Investor Briefing February 28, 2018

Q Analyst and Investor Briefing February 28, 2018 Q4 217 Analyst and Investor Briefing February 28, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Q4 217: Sales at 8,596 million (+2.7% Fx & portf. adj.) EBITDA before special

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Q3 2017 Results October 26, 2017 / Werner Baumann, CEO Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute

More information

Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation

Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation Investor Conference Call May 6, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers May 6, 2014 Disclaimer This

More information

Q Analyst and Investor Briefing September 5, 2018

Q Analyst and Investor Briefing September 5, 2018 Q2 218 Analyst and Investor Briefing September 5, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer completes biggest acquisition in its history Monsanto business included

More information

Financial Targets through 2022: Focus on Value Creation

Financial Targets through 2022: Focus on Value Creation Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information

More information

CEO Werner Baumann at the Annual Stockholders Meeting of Bayer AG:

CEO Werner Baumann at the Annual Stockholders Meeting of Bayer AG: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com CEO Werner Baumann at the Annual Stockholders Meeting of Bayer AG: Bayer is making good progress strategically

More information

Investor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014:

Investor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2014: Bayer: strong business momentum continues and portfolio transformation underway Group portfolio to

More information

Non-Deal Debt Roadshow

Non-Deal Debt Roadshow Science For A Better Life Non-Deal Debt Roadshow Johannes M. Dietsch, Finance Director December 2007 Bayer Non-Deal Debt Roadshow December 2007 Disclaimer This presentation contains forward-looking statements

More information

Another record year for Bayer good progress with the acquisition of Monsanto

Another record year for Bayer good progress with the acquisition of Monsanto News Release Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Phone +49 214 30-0 www.news.bayer.com Fiscal 2016: Another record year for Bayer good progress with the acquisition of Monsanto

More information

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has outstanding perspectives as a pure

More information

Investor News. Another record year for Bayer. Fiscal 2015:

Investor News. Another record year for Bayer. Fiscal 2015: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2015: Another record year for Bayer Focus on the Life Sciences following the successful stock market flotation

More information

Investor Handout Q3 2014

Investor Handout Q3 2014 Investor Handout Q3 2014 November 2014 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and

More information

Investor Conference Call

Investor Conference Call Investor Conference Call FY/Q4 2014 Results February 26, 2015 / Marijn Dekkers, CEO Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by

More information

Investor Handout Q2 2013

Investor Handout Q2 2013 Investor Handout Q2 2013 August 2013 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown

More information

Investor Conference Call

Investor Conference Call Investor Conference Call FY/Q4 2015 Results February 25, 2016 / Marijn Dekkers, CEO Page 1 Q4/FY 2015 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements

More information

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Innovation is our future 2015 was a very successful

More information

Full Year million Q Q Change % 9M M 2017 Change % 2016

Full Year million Q Q Change % 9M M 2017 Change % 2016 Interim Report Third Quarter of 207 Bayer Interim Report as of September 30, 207 Key Data 2 Bayer Group Key Data Full Year million Q3 206 Q3 207 Change % 9M 206 9M 207 Change % 206 Sales 8,258 8,025 2.8

More information

Interim Report Second Quarter of 2017

Interim Report Second Quarter of 2017 Interim Report Second Quarter of 207 Bayer Interim Report as of June 30, 207 Key Data 2 Bayer Group Key Data million Q2 206 Q2 207 Change % H 206 H 207 Change % Full Year 206 Sales,833 2,93 + 3.0 23,687

More information

Investor Handout. Roadshow California

Investor Handout. Roadshow California Investor Handout Roadshow California July 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup

More information

UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG

UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG September 20, 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and

More information

Q Analyst and Investor Briefing March 3, 2009

Q Analyst and Investor Briefing March 3, 2009 Q4 2008 Analyst and Investor Briefing March 3, 2009 Sales declined by 1.5% to 7,923m (Q4 07: 8,040m); Volume -5.7%, price +1.7%, currency +2.0%, portfolio +0.6%. Portfolio and Fx adj. sales dropped by

More information

Investor Handout Q April 2012 I Leverkusen

Investor Handout Q April 2012 I Leverkusen Investor Handout Q1 2012 April 2012 I Leverkusen Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup

More information

Building Growth Momentum in HealthCare

Building Growth Momentum in HealthCare Building Growth Momentum in HealthCare Marijn Dekkers, CEO September 20, 2011 UBS Life Science Conference Disclaimer This presentation may contain forward-looking statements based on current assumptions

More information

Investor Handout. Roadshow Scandinavia

Investor Handout. Roadshow Scandinavia Investor Handout Roadshow Scandinavia June 15/16, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group

More information

First Quarter of 2018

First Quarter of 2018 Q Interim Report First Quarter of 208 Bayer Interim Report as of March 3, 208 Key Data 2 Bayer Group Key Data Full Year million Q 207 Q 208 Change % 207 Sales 9,680 9,38 5.6 35,05 Change (adjusted for

More information

Full Year million Q Q Change % 2016

Full Year million Q Q Change % 2016 Interim Report First Quarter of 207 Bayer Interim Report as of March 3, 207 Key Data 2 Bayer Group Key Data Full Year million Q 206 Q 207 Change % 206 Sales,854 3,244 +.7 46,769 Change (adjusted for currency

More information

Interim Report. Third Quarter of Bayer posts strong earnings growth

Interim Report. Third Quarter of Bayer posts strong earnings growth Interim Report Third of Bayer posts strong earnings growth 2 Bayer Interim Report Key Data Bayer Group Key Data Change Change Full Year million million % million million % million Sales 9,967 11,036 +

More information

Investor Handout Roadshow London Marijn Dekkers, CEO

Investor Handout Roadshow London Marijn Dekkers, CEO Investor Handout Roadshow London Marijn Dekkers, CEO May 25-26, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by

More information

Investor Conference. London, August 6, First Half 2003 Results

Investor Conference. London, August 6, First Half 2003 Results Investor Conference London, August 6, 23 First Half 23 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.

More information

Q Analyst and Investor Briefing July 31, 2012

Q Analyst and Investor Briefing July 31, 2012 Q2 212 Analyst and Investor Briefing July 31, 212 Bayer raises guidance for the full year Strong business performance in the second quarter of 212 Record sales 1.2 billion (+5.% Fx and portfolio adjusted)

More information

Akorn, Inc. N a s d a q : A K R X

Akorn, Inc. N a s d a q : A K R X Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our

More information

Q Analyst and Investor Briefing October 27, 2009

Q Analyst and Investor Briefing October 27, 2009 Q3 2009 Analyst and Investor Briefing October 27, 2009 Sales declined by 7.0% to 7,392m (Q3 08: 7,948m); volume -2.8%, price -4.4%, currency +0.6%, portfolio -0.4%. Portfolio and Fx adj. sales dropped

More information

Q Analyst and Investor Briefing February 26, 2010

Q Analyst and Investor Briefing February 26, 2010 Q4 2009 Analyst and Investor Briefing February 26, 2010 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Sales declined by 0.6% to 7,872m (Q4 08: 7,923m); volume 8.2%, price

More information

UniCredit German Investment Conference. Building growth momentum. Dr. Alexander Rosar Head of Investor Relations. 2011, September 29, Munich

UniCredit German Investment Conference. Building growth momentum. Dr. Alexander Rosar Head of Investor Relations. 2011, September 29, Munich UniCredit German Investment Conference Building growth momentum Dr. Alexander Rosar Head of Investor Relations 2011, September 29, Munich Disclaimer This presentation may contain forward-looking statements

More information

Investor Conference Call FY/Q Results

Investor Conference Call FY/Q Results For A Better Life Investor Conference Call FY/Q4 2006 Results Werner Wenning, CEO March 15 2007 Disclaimer This presentation contains forward-looking statements based on current assumptions and forecasts

More information

Investor Conference Call FY/Q Results

Investor Conference Call FY/Q Results Science For A Better Life Investor Conference Call FY/Q4 Results Werner Wenning, CEO February 26 2010 FY/Q4 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking

More information

Disclaimer. Building growth momentum. Roadshow The Netherlands / Brussels

Disclaimer. Building growth momentum. Roadshow The Netherlands / Brussels Building growth momentum Roadshow The Netherlands / Brussels October 4-5, 2011 Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer

More information

September 18, 2014 / Marijn Dekkers, CEO

September 18, 2014 / Marijn Dekkers, CEO Transforming Bayer into a Pure Life Company - Exit of Material September 18, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers September 18, 2014 Disclaimer This presentation may

More information

Creating Value by Accelerating Transformation & Growth

Creating Value by Accelerating Transformation & Growth Creating Value by Accelerating Transformation & Growth Univar Announces Agreement to Acquire Nexeo September 17, 2018 1 2018 Univar, Inc. All rights reserved. Forward-Looking Statements This communication

More information

FIRST QUARTER Financial Results January 5, 2017

FIRST QUARTER Financial Results January 5, 2017 FIRST QUARTER 2017 Financial Results January 5, 2017 Forward Looking Statements Trademarks Trademarks owned by Monsanto Company and its wholly-owned subsidiaries are italicized in this presentation. All

More information

Jazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination. Bruce Cozadd, Chairman and CEO

Jazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination. Bruce Cozadd, Chairman and CEO Jazz Pharmaceuticals and Azur Pharma A Compelling Strategic Combination Bruce Cozadd, Chairman and CEO Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform

More information

Q Analyst and Investor Briefing April 29, 2009

Q Analyst and Investor Briefing April 29, 2009 Q1 2009 Analyst and Investor Briefing April 29, 2009 Sales declined by 7.5% to 7,895m (Q1 08: 8,536m); Volume -9.4%, price -0.3%, currency +1.9%, portfolio +0.3%. Portfolio and Fx adj. sales dropped by

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Q3 2014 Results October 30, 2014 / Marijn Dekkers, CEO Page 1 Q3 2014 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements

More information

Science For A Better Life. Investor Handout Q V Oct 08

Science For A Better Life. Investor Handout Q V Oct 08 Science For A Better Life Investor Handout Q3 2008 V Oct 08 Important Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group

More information

Interim Report. First Quarter of Strong start to the year for Bayer

Interim Report. First Quarter of Strong start to the year for Bayer Interim Report First Quarter of Strong start to the year for Bayer 2 Bayer Interim Report Key Data Bayer Group Key Data Change Full Year million million % million Sales 10,555 12,117 + 14.8 42,239 Change

More information

Lehman Conference, April 2003

Lehman Conference, April 2003 Lehman Conference, April 2003 Klaus Kühn, CFO of Bayer AG Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various

More information

Reinvigorating Our Leading OTC Position

Reinvigorating Our Leading OTC Position Reinvigorating Our Leading OTC Position /////////// Capital Markets Day London, December 5, 2018 Heiko Schipper Head of Consumer Health Disclaimer Cautionary Statements Regarding Forward-Looking Information

More information

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: News Release Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-1 www.news.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer

More information

Amcor & Bemis Combination Creating the Global Leader in Consumer Packaging. 6 August 2018

Amcor & Bemis Combination Creating the Global Leader in Consumer Packaging. 6 August 2018 Amcor & Bemis Combination Creating the Global Leader in Consumer Packaging 6 August 2018 Disclaimer Cautionary Statement Regarding Forward-Looking Statements This communication contains certain statements

More information

United Rentals to Acquire RSC Holdings

United Rentals to Acquire RSC Holdings United Rentals to Acquire RSC Holdings Investor Presentation DECEMBER 2011 Introductory Information Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements

More information

Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO

Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.

More information

Acquisition Offer of RPC Group PLC

Acquisition Offer of RPC Group PLC Always Advancing To Protect What s Important Acquisition Offer of RPC Group PLC March 2019 NYSE: BERY Safe Harbor Statements THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,

More information

Science For A Better Life. UniCredit German Investment Conference. Dr. Alexander Rosar Head of Investor Relations September

Science For A Better Life. UniCredit German Investment Conference. Dr. Alexander Rosar Head of Investor Relations September Science For A Better Life UniCredit German Investment Conference Dr. Alexander Rosar Head of Investor Relations September 24 2008 V Sept08 Me Important Information This presentation may contain forward-looking

More information

Fourth Quarter and Full Year 2017 Results. March 1, 2018

Fourth Quarter and Full Year 2017 Results. March 1, 2018 1 Fourth Quarter and Full Year 2017 Results March 1, 2018 Impax Cautionary Statement Regarding Forward Looking Statements 2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of

More information

FINANCIAL OVERVIEW AL MISTYSYN SENIOR VICE PRESIDENT, FINANCE & CHIEF FINANCIAL OFFICER FINANCIAL COMMUNITY PRESENTATION OCTOBER 3, 2017

FINANCIAL OVERVIEW AL MISTYSYN SENIOR VICE PRESIDENT, FINANCE & CHIEF FINANCIAL OFFICER FINANCIAL COMMUNITY PRESENTATION OCTOBER 3, 2017 FINANCIAL OVERVIEW AL MISTYSYN SENIOR VICE PRESIDENT, FINANCE & CHIEF FINANCIAL OFFICER FINANCIAL COMMUNITY PRESENTATION OCTOBER 3, 2017 Forward Looking Statement The presentations today will contain certain

More information

Q Analyst and Investor Briefing October 28, 2010

Q Analyst and Investor Briefing October 28, 2010 Q3 21 Analyst and Investor Briefing October 28, 21 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Further growth in Group sales and underlying EBITDA mainly driven by business

More information

Financial results & business update. Quarter ended 30 September October 2016

Financial results & business update. Quarter ended 30 September October 2016 Financial results & business update Quarter ended 30 September 2016 19 October 2016 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking

More information

Fiserv to Combine with First Data to Create Global Leader in Payments and FinTech

Fiserv to Combine with First Data to Create Global Leader in Payments and FinTech Fiserv to Combine with First Data to Create Global Leader in Payments and FinTech Investor Presentation January 6, 209 Forward Looking Statements The information disclosed in this presentation contains

More information

Investor Handout Q Results

Investor Handout Q Results Investor Handout Q3 2002 Results Table Of Contents Safe Harbour 1 Performance 2 A Far-Reaching Transformation 12 Strategic Priorities 19 Financials 29 2 Safe Harbor This presentation contains forward-looking

More information

Accelerating our IPT strategy

Accelerating our IPT strategy Accelerating our IPT strategy GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture Transaction lays foundation for separation of GSK to create two new UK-based

More information

Building Growth Momentum in HealthCare. 30 th Annual J.P. Morgan Healthcare Conference

Building Growth Momentum in HealthCare. 30 th Annual J.P. Morgan Healthcare Conference 30 th Annual J.P. Morgan Healthcare Conference Building Growth Momentum in HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management Bayer HealthCare 2012, January 10, San Francisco Disclaimer

More information

Shareholders Expected to Benefit from a Number of Outcomes

Shareholders Expected to Benefit from a Number of Outcomes Shareholders Expected to Benefit from a Number of Outcomes Benefits for Shareholders F I N A N C I A L S U P P L E M E N T Enhanced competitive positioning Low- to mid-single digit accretion in the second

More information

july 2012 CEB to Acquire SHL Compelling Value Creation, Growth, and Scale Opportunity

july 2012 CEB to Acquire SHL Compelling Value Creation, Growth, and Scale Opportunity july 2012 CEB to Acquire SHL Compelling Value Creation, Growth, and Scale Opportunity Safe Harbor Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities

More information

Fiscal Year rd Quarter Earnings Conference Call

Fiscal Year rd Quarter Earnings Conference Call Fiscal Year 2017 3 rd Quarter Earnings Conference Call August 8, 2017 www.jacobs.com worldwide Forward-Looking Statement Disclaimer Certain statements contained in this presentation constitute forward-looking

More information

MERCK KGAA, DARMSTADT, GERMANY

MERCK KGAA, DARMSTADT, GERMANY MERCK KGAA, DARMSTADT, GERMANY PREPARING STRATEGIC OPTIONS FOR CONSUMER HEALTH Belén Garijo, CEO Healthcare Marcus Kuhnert, CFO September 5, 2017 Disclaimer Publication of Merck KGaA, Darmstadt, Germany.

More information

September 11, Corporate Update. Rich Tobin, President & Chief Executive Officer

September 11, Corporate Update. Rich Tobin, President & Chief Executive Officer September 11, 2018 Corporate Update Rich Tobin, President & Chief Executive Officer Forward-Looking Statements and Non-GAAP Measures Our comments may contain forward-looking statements that are inherently

More information

Endo Health Solutions

Endo Health Solutions Endo Health Solutions 3Q 2013 Earnings Report and A Compelling Combination: Endo Health Solutions and Paladin Labs November 5, 2013 Offer Language Disclosures This communication is not intended to and

More information

Energizer Investor Call. November 15, 2018

Energizer Investor Call. November 15, 2018 Energizer Investor Call November 15, 2018 Cautionary Note Regarding Forward- Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation

More information

SENSATA FOURTH QUARTER AND FULL YEAR 2017 EARNINGS PRESENTATION FEBRUARY 1, 2018

SENSATA FOURTH QUARTER AND FULL YEAR 2017 EARNINGS PRESENTATION FEBRUARY 1, 2018 SENSATA FOURTH QUARTER AND FULL YEAR 2017 EARNINGS PRESENTATION FEBRUARY 1, 2018 Forward-Looking Statements This earnings presentation contains "forward-looking statements" within the meaning of Section

More information

Q Analyst and Investor Briefing July 28, 2011

Q Analyst and Investor Briefing July 28, 2011 Q2 211 Analyst and Investor Briefing July 28, 211 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Group sales at 9,252 million, up 5.4% (portfolio and currency adjusted) Price

More information

Meta Financial Group, Inc. Transformational Merger with Crestmark Bancorp, Inc. Investor Presentation January 9, 2018

Meta Financial Group, Inc. Transformational Merger with Crestmark Bancorp, Inc. Investor Presentation January 9, 2018 Meta Financial Group, Inc. Transformational Merger with Crestmark Bancorp, Inc. Investor Presentation January 9, 2018 Forward-Looking Statements Meta Financial Group, Inc. (the Company or Meta ) and its

More information

LyondellBasell Acquisition of A. Schulman

LyondellBasell Acquisition of A. Schulman LyondellBasell Acquisition of A. Schulman Creating an Advanced Polymer Solutions Leader February 15, 2018 1 Cautionary Note Regarding Forward-looking Statements The statements in this communication relating

More information

Stockholders Newsletter Financial Report as of September 30, 2013

Stockholders Newsletter Financial Report as of September 30, 2013 Stockholders Newsletter Financial Report as of September 30, k Cover Picture Third quarter of : Bayer continues positive business momentum Contents Interim Group management Report as of September 30,...4

More information

INVESTOR PRESENTATION. Nasdaq London Conference November 2016

INVESTOR PRESENTATION. Nasdaq London Conference November 2016 INVESTOR PRESENTATION Nasdaq London Conference November 2016 DISCLAIMERS Non-GAAP Information In addition to disclosing results determined in accordance with U.S. GAAP, Nasdaq also discloses certain non-gaap

More information

To Acquire. Creating the first and only global, comprehensive virtual healthcare delivery platform. June 19, 2017

To Acquire. Creating the first and only global, comprehensive virtual healthcare delivery platform. June 19, 2017 To Acquire Creating the first and only global, comprehensive virtual healthcare delivery platform June 19, 2017 1 Today s Presenters Jason Gorevic President & CEO Mark Hirschhorn COO & CFO Peter McClennen

More information

DENTSPLY and Sirona Announce Combination to Create The Dental Solutions Company in $13 Billion Merger of Equals

DENTSPLY and Sirona Announce Combination to Create The Dental Solutions Company in $13 Billion Merger of Equals FOR IMMEDIATE RELEASE DENTSPLY and Sirona Announce Combination to Create The Dental Solutions Company in $13 Billion Merger of Equals Combination of Leading Platforms in Consumables, Equipment and Technology

More information

GRANITE CONSTRUCTION TO ACQUIRE LAYNE CHRISTENSEN

GRANITE CONSTRUCTION TO ACQUIRE LAYNE CHRISTENSEN GRANITE CONSTRUCTION TO ACQUIRE LAYNE CHRISTENSEN A PLATFORM FOR GROWTH FEBRUARY 2018 Safe Harbor Forward Looking Statements All statements included or incorporated by reference in this communication,

More information

Pentair KeyBanc Capital Markets Industrial, Automotive & Transportation Conference

Pentair KeyBanc Capital Markets Industrial, Automotive & Transportation Conference Pentair KeyBanc Capital Markets Industrial, Automotive & Transportation Conference John L. Stauch Chief Financial Officer May30, 2013 PENTAIR FORWARD-LOOKING STATEMENTS CAUTION CONCERNING FORWARD-LOOKING

More information

Akorn, Inc. N a s d a q : A K R X

Akorn, Inc. N a s d a q : A K R X Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global London Healthcare Conference November 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect

More information

NYSE EURONEXT FIRST QUARTER 2013 EARNINGS PRESENTATION. April 30, 2013

NYSE EURONEXT FIRST QUARTER 2013 EARNINGS PRESENTATION. April 30, 2013 NYSE EURONEXT FIRST QUARTER 2013 EARNINGS PRESENTATION April 30, 2013 LEGAL DISCLAIMERS Non-GAAP Financial Measures To supplement NYSE Euronext s consolidated financial statements prepared in accordance

More information

June Dear Fellow Takeda Shareholder,

June Dear Fellow Takeda Shareholder, June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in

More information

AIG Acquisition of Validus Holdings: A Step Forward in AIG s Profitable Growth Strategy. Investor Presentation January 22, 2018

AIG Acquisition of Validus Holdings: A Step Forward in AIG s Profitable Growth Strategy. Investor Presentation January 22, 2018 AIG Acquisition of Validus Holdings: A Step Forward in AIG s Profitable Growth Strategy Investor Presentation January 22, 2018 Disclaimer Forward-Looking Statements Certain statements in this presentation

More information

Unsaved Document / 9/18/2010 / 13:49. Proposed Acquisition of GAIN Capital Holdings, Inc. April 9, 2013

Unsaved Document / 9/18/2010 / 13:49. Proposed Acquisition of GAIN Capital Holdings, Inc. April 9, 2013 Unsaved Document / 9/18/2010 / 13:49 Proposed Acquisition of GAIN Capital Holdings, Inc. April 9, 2013 Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A

More information

Heading back to profitable growth

Heading back to profitable growth Commerzbank German Investment Seminar 2010 New York January 12, 2010 Dr. Kurt Bock, CFO Heading back to profitable growth 1 Forward-looking statements This presentation includes forward-looking statements

More information

Safe Harbor Pages. Forward Looking Statements

Safe Harbor Pages. Forward Looking Statements December 2010 Safe Harbor Pages Forward Looking Statements To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking statements

More information

ZOETIS TO ACQUIRE ABAXIS. May 16, 2018

ZOETIS TO ACQUIRE ABAXIS. May 16, 2018 ZOETIS TO ACQUIRE ABAXIS May 16, 2018 1 1 ACCELERATING GROWTH TOGETHER 2 2 FORWARD-LOOKING STATEMENTS Statements included in this communication which are not historical in nature or do not relate to current

More information

Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals

Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals FOR IMMEDIATE RELEASE Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals Mails Letter to Shareholders Highlighting Accelerated Growth

More information

Raymond James 37 th Annual Institutional Investors Conference. March 8, 2016

Raymond James 37 th Annual Institutional Investors Conference. March 8, 2016 Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Forward-looking statements and Non-GAAP financial measures Forward-looking statements Certain statements included in this presentation,

More information

Jefferies Industrials Conference. August 11, 2015

Jefferies Industrials Conference. August 11, 2015 Jefferies Industrials Conference August 11, 2015 Forward-Looking Statements & Accounting Standards Cautionary Statement on Forward-Looking Statements: This document contains forward-looking statements

More information

36 th Annual J.P. Morgan Healthcare Conference. January 10, 2018

36 th Annual J.P. Morgan Healthcare Conference. January 10, 2018 36 th Annual J.P. Morgan Healthcare Conference January 10, 2018 Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes information that may constitute forward-looking statements,

More information

Worldline H Results Worldline. Presentation to Investors September 2018

Worldline H Results Worldline. Presentation to Investors September 2018 Presentation to Investors September 2018 Disclaimer This document contains forward-looking statements that involve risks and uncertainties, including references, concerning the Group's expected growth

More information

Driven to Create Value Goldman Sachs 2017 Global Energy Conference January 2017

Driven to Create Value Goldman Sachs 2017 Global Energy Conference January 2017 Driven to Create Value Goldman Sachs 2017 Global Energy Conference January 2017 2015 Corporation. All Rights Reserved. Forward Looking Statements On November 17, 2016, we announced our plans to acquire

More information

Life Sciences and Materials Sciences Rolf-Dieter Schwalb, CFO Royal DSM. Capital Markets Day, 5 November Page

Life Sciences and Materials Sciences Rolf-Dieter Schwalb, CFO Royal DSM. Capital Markets Day, 5 November Page Life Sciences and Materials Sciences Rolf-Dieter Schwalb, CFO Royal DSM Capital Markets Day, 5 November 2014 Safe harbor statement This presentation may contain forward-looking statements with respect

More information

Third Quarter Results 2005

Third Quarter Results 2005 Science For A Better Life Company Presentation Third Quarter Results 25 Forward Looking Statements This presentation contains forward-looking statements based on current assumptions and forecasts made

More information

LogMeIn Announces Merger with Citrix s GoTo Family of Products to Create a Billion Dollar Industry Leader

LogMeIn Announces Merger with Citrix s GoTo Family of Products to Create a Billion Dollar Industry Leader LogMeIn Announces Merger with Citrix s GoTo Family of Products to Create a Billion Dollar Industry Leader J U LY 2 6 T H, 2 0 1 6 Safe Harbor Statement This communication contains forward-looking statements

More information